{"transactions":[{"id":3987353,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-03-20T18:30:36.000Z","date":"2018-03-20","kind":"sale","acquired":false,"shares":3000,"price":38.83,"value":116490.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.50 to $39.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":88762,"source":{"system":"sec-edgar","filing":"0001209191-18-020971","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118020971/doc4.xml","form_type":"4"}},{"id":3987352,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-03-20T18:30:36.000Z","date":"2018-03-19","kind":"sale","acquired":false,"shares":3000,"price":41.99,"value":125970.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.90 to $42.075. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":91762,"source":{"system":"sec-edgar","filing":"0001209191-18-020971","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118020971/doc4.xml","form_type":"4"}},{"id":4047112,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-02-20T20:22:49.000Z","date":"2018-02-15","kind":"exercise","acquired":false,"shares":5132,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015.  The service-based vesting condition provides that 25% of the total number of shares on January 6, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The earlier of (i) December 12, 2020 or (ii) the recipient's termination date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5132},"source":{"system":"sec-edgar","filing":"0001209191-18-011664","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118011664/doc4.xml","form_type":"4"}},{"id":4047111,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-20T20:22:49.000Z","date":"2018-02-16","kind":"sale","acquired":false,"shares":2500,"price":48.08,"value":120200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $47.70 to $48.325. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":94762,"source":{"system":"sec-edgar","filing":"0001209191-18-011664","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118011664/doc4.xml","form_type":"4"}},{"id":4047110,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-20T20:22:49.000Z","date":"2018-02-16","kind":"sale","acquired":false,"shares":4000,"price":46.93,"value":187720.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.65 to $47.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":97262,"source":{"system":"sec-edgar","filing":"0001209191-18-011664","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118011664/doc4.xml","form_type":"4"}},{"id":4047109,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-20T20:22:49.000Z","date":"2018-02-15","kind":"tax_withholding","acquired":false,"shares":2926,"price":47.05,"value":137668.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Shares withheld to cover tax obligation from settlement of vested restricted stock units."}],"balance_after":101262,"source":{"system":"sec-edgar","filing":"0001209191-18-011664","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118011664/doc4.xml","form_type":"4"}},{"id":4047108,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-20T20:22:49.000Z","date":"2018-02-15","kind":"exercise","acquired":true,"shares":5132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":104188,"source":{"system":"sec-edgar","filing":"0001209191-18-011664","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118011664/doc4.xml","form_type":"4"}},{"id":4047107,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-20T20:22:49.000Z","date":"2018-02-15","kind":"sale","acquired":false,"shares":6500,"price":46.77,"value":304005.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.50 to $47.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":99056,"source":{"system":"sec-edgar","filing":"0001209191-18-011664","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118011664/doc4.xml","form_type":"4"}},{"id":4065792,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-12T20:54:32.000Z","date":"2018-02-09","kind":"tax_withholding","acquired":false,"shares":4819,"price":41.7,"value":200952.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to cover tax obligation from settlement of vested restricted stock units."}],"balance_after":105556,"source":{"system":"sec-edgar","filing":"0001209191-18-009405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118009405/doc4.xml","form_type":"4"}},{"id":4070175,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-02-08T17:43:17.000Z","date":"2018-02-06","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2018."}],"balance_after":50000,"derivative":{"exercise_price":35.8,"expiration_date":"2025-02-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-18-008508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118008508/doc4.xml","form_type":"4"}},{"id":4070174,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-08T17:43:17.000Z","date":"2018-02-06","kind":"tax_withholding","acquired":false,"shares":4279,"price":35.8,"value":153188.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld to cover tax obligation from settlement of vested restricted stock units."}],"balance_after":110375,"source":{"system":"sec-edgar","filing":"0001209191-18-008508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118008508/doc4.xml","form_type":"4"}},{"id":4070173,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-08T17:43:17.000Z","date":"2018-02-06","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service."}],"balance_after":114654,"source":{"system":"sec-edgar","filing":"0001209191-18-008508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118008508/doc4.xml","form_type":"4"}},{"id":4100315,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-01-12T19:56:10.000Z","date":"2018-01-12","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the stock option vest and become exercisable each month following October 15, 2014."}],"balance_after":10000,"derivative":{"exercise_price":11,"expiration_date":"2021-10-14","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-18-003485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118003485/doc4.xml","form_type":"4"}},{"id":4100314,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-01-12T19:56:10.000Z","date":"2018-01-12","kind":"sale","acquired":false,"shares":30000,"price":25,"value":750000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $25.00 to $25.025. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":89654,"source":{"system":"sec-edgar","filing":"0001209191-18-003485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118003485/doc4.xml","form_type":"4"}},{"id":4100313,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-01-12T19:56:10.000Z","date":"2018-01-12","kind":"sale","acquired":false,"shares":3500,"price":22.32,"value":78120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.15 to $22.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":119654,"source":{"system":"sec-edgar","filing":"0001209191-18-003485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118003485/doc4.xml","form_type":"4"}},{"id":4100312,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-01-12T19:56:10.000Z","date":"2018-01-12","kind":"exercise","acquired":true,"shares":30000,"price":11,"value":330000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."}],"balance_after":123154,"source":{"system":"sec-edgar","filing":"0001209191-18-003485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118003485/doc4.xml","form_type":"4"}},{"id":4100311,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-01-12T19:56:10.000Z","date":"2018-01-11","kind":"sale","acquired":false,"shares":3500,"price":20.77,"value":72695.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.70 to $20.925. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":93154,"source":{"system":"sec-edgar","filing":"0001209191-18-003485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118003485/doc4.xml","form_type":"4"}},{"id":4116909,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-01-02T19:14:59.000Z","date":"2017-12-29","kind":"sale","acquired":false,"shares":32000,"price":20,"value":640000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."}],"balance_after":96654,"source":{"system":"sec-edgar","filing":"0001209191-18-000376","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919118000376/doc4.xml","form_type":"4"}},{"id":4157848,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2017-11-17T18:24:49.000Z","date":"2017-11-15","kind":"exercise","acquired":false,"shares":7697,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015.  The service-based vesting condition provides that 25% of the total number of shares on January 6, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The earlier of (i) December 12, 2020 or (ii) the recipient's termination date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee."}],"balance_after":5132,"derivative":{"underlying":"Common Stock","underlying_shares":7697},"source":{"system":"sec-edgar","filing":"0001209191-17-061602","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117061602/doc4.xml","form_type":"4"}},{"id":4157847,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-11-17T18:24:49.000Z","date":"2017-11-15","kind":"exercise","acquired":true,"shares":7697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":128654,"source":{"system":"sec-edgar","filing":"0001209191-17-061602","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117061602/doc4.xml","form_type":"4"}},{"id":4230487,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2017-08-17T17:36:39.000Z","date":"2017-08-15","kind":"exercise","acquired":false,"shares":7697,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015.  The service-based vesting condition provides that 25% of the total number of shares on January 6, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The earlier of (i) December 12, 2020 or (ii) the recipient's termination date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee."}],"balance_after":12829,"derivative":{"underlying":"Common Stock","underlying_shares":7697},"source":{"system":"sec-edgar","filing":"0001209191-17-049449","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117049449/doc4.xml","form_type":"4"}},{"id":4230486,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-08-17T17:36:39.000Z","date":"2017-08-16","kind":"sale","acquired":false,"shares":2100,"price":14.39,"value":30219.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.05 to $14.60. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":120957,"source":{"system":"sec-edgar","filing":"0001209191-17-049449","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117049449/doc4.xml","form_type":"4"}},{"id":4230485,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-08-17T17:36:39.000Z","date":"2017-08-15","kind":"sale","acquired":false,"shares":2100,"price":14.23,"value":29883.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.20 to $14.275. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":123057,"source":{"system":"sec-edgar","filing":"0001209191-17-049449","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117049449/doc4.xml","form_type":"4"}},{"id":4230484,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-08-17T17:36:39.000Z","date":"2017-08-15","kind":"exercise","acquired":true,"shares":7697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":125157,"source":{"system":"sec-edgar","filing":"0001209191-17-049449","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117049449/doc4.xml","form_type":"4"}},{"id":4315363,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2017-05-17T17:01:55.000Z","date":"2017-05-15","kind":"exercise","acquired":false,"shares":7698,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015.  The service-based vesting condition provides that 25% of the total number of shares on January 6, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The earlier of (i) December 12, 2020 or (ii) the recipient's termination date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee."}],"balance_after":20526,"derivative":{"underlying":"Common Stock","underlying_shares":7698},"source":{"system":"sec-edgar","filing":"0001209191-17-033208","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117033208/doc4.xml","form_type":"4"}},{"id":4315362,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2017-05-17T17:01:55.000Z","date":"2017-05-15","kind":"exercise","acquired":false,"shares":935,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015.  The service-based vesting condition provides that 25% of the total number of shares on March 13, 2014 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The earlier of (i) March 13, 2020 or (ii) the recepient's termination date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":935},"source":{"system":"sec-edgar","filing":"0001209191-17-033208","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117033208/doc4.xml","form_type":"4"}},{"id":4315361,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-05-17T17:01:55.000Z","date":"2017-05-16","kind":"sale","acquired":false,"shares":2000,"price":15.27,"value":30540.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.20 to $15.30. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":117460,"source":{"system":"sec-edgar","filing":"0001209191-17-033208","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117033208/doc4.xml","form_type":"4"}},{"id":4315360,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-05-17T17:01:55.000Z","date":"2017-05-15","kind":"sale","acquired":false,"shares":2000,"price":14.95,"value":29900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.70 to $15.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":119460,"source":{"system":"sec-edgar","filing":"0001209191-17-033208","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117033208/doc4.xml","form_type":"4"}},{"id":4315359,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-05-17T17:01:55.000Z","date":"2017-05-15","kind":"exercise","acquired":true,"shares":7698,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":121460,"source":{"system":"sec-edgar","filing":"0001209191-17-033208","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117033208/doc4.xml","form_type":"4"}},{"id":4315358,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-05-17T17:01:55.000Z","date":"2017-05-15","kind":"exercise","acquired":true,"shares":935,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":113762,"source":{"system":"sec-edgar","filing":"0001209191-17-033208","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117033208/doc4.xml","form_type":"4"}},{"id":4373440,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-23T20:06:18.000Z","date":"2017-03-23","kind":"sale","acquired":false,"shares":6500,"price":21.08,"value":137020.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.80 to $21.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":112827,"source":{"system":"sec-edgar","filing":"0001209191-17-022684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117022684/doc4.xml","form_type":"4"}},{"id":4373439,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-23T20:06:18.000Z","date":"2017-03-22","kind":"sale","acquired":false,"shares":7500,"price":20.27,"value":152025.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.10 to $20.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":119327,"source":{"system":"sec-edgar","filing":"0001209191-17-022684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117022684/doc4.xml","form_type":"4"}},{"id":4390497,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-10T19:57:27.000Z","date":"2017-03-10","kind":"sale","acquired":false,"shares":24000,"price":20,"value":480000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."}],"balance_after":126827,"source":{"system":"sec-edgar","filing":"0001209191-17-019981","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117019981/doc4.xml","form_type":"4"}},{"id":4431082,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-02-22T17:32:55.000Z","date":"2017-02-21","kind":"sale","acquired":false,"shares":9000,"price":15.14,"value":136260.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.90 to $15.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":150827,"source":{"system":"sec-edgar","filing":"0001209191-17-013442","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117013442/doc4.xml","form_type":"4"}},{"id":4442253,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2017-02-16T20:11:29.000Z","date":"2017-02-15","kind":"exercise","acquired":false,"shares":7697,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015.  The service-based vesting condition provides that 25% of the total number of shares on January 6, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The earlier of (i) December 12, 2020 or (ii) the recipient's termination date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee."}],"balance_after":28224,"derivative":{"underlying":"Common Stock","underlying_shares":7697},"source":{"system":"sec-edgar","filing":"0001209191-17-011768","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117011768/doc4.xml","form_type":"4"}},{"id":4442252,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2017-02-16T20:11:29.000Z","date":"2017-02-15","kind":"exercise","acquired":false,"shares":2804,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015.  The service-based vesting condition provides that 25% of the total number of shares on March 13, 2014 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The earlier of (i) March 13, 2020 or (ii) the recepient's termination date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee."}],"balance_after":935,"derivative":{"underlying":"Common Stock","underlying_shares":2804},"source":{"system":"sec-edgar","filing":"0001209191-17-011768","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117011768/doc4.xml","form_type":"4"}},{"id":4442251,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-02-16T20:11:29.000Z","date":"2017-02-15","kind":"exercise","acquired":true,"shares":7697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":159827,"source":{"system":"sec-edgar","filing":"0001209191-17-011768","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117011768/doc4.xml","form_type":"4"}},{"id":4442250,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-02-16T20:11:29.000Z","date":"2017-02-15","kind":"exercise","acquired":true,"shares":2804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":152130,"source":{"system":"sec-edgar","filing":"0001209191-17-011768","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117011768/doc4.xml","form_type":"4"}},{"id":4461310,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-02-08T17:37:15.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":49500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service."}],"balance_after":149326,"source":{"system":"sec-edgar","filing":"0001209191-17-008827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919117008827/doc4.xml","form_type":"4"}},{"id":4550086,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2016-11-17T16:53:57.000Z","date":"2016-11-15","kind":"exercise","acquired":false,"shares":7698,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015.  The service-based vesting condition provides that 25% of the total number of shares on January 6, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The earlier of (i) December 12, 2020 or (ii) the recipient's termination date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee."}],"balance_after":35921,"derivative":{"underlying":"Common Stock","underlying_shares":7698},"source":{"system":"sec-edgar","filing":"0001209191-16-150916","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919116150916/doc4.xml","form_type":"4"}},{"id":4550085,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2016-11-17T16:53:57.000Z","date":"2016-11-15","kind":"exercise","acquired":false,"shares":2805,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015.  The service-based vesting condition provides that 25% of the total number of shares on March 13, 2014 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The earlier of (i) March 13, 2020 or (ii) the recepient's termination date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee."}],"balance_after":3739,"derivative":{"underlying":"Common Stock","underlying_shares":2805},"source":{"system":"sec-edgar","filing":"0001209191-16-150916","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919116150916/doc4.xml","form_type":"4"}},{"id":4550084,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-11-17T16:53:57.000Z","date":"2016-11-15","kind":"exercise","acquired":true,"shares":7698,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":99826,"source":{"system":"sec-edgar","filing":"0001209191-16-150916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919116150916/doc4.xml","form_type":"4"}},{"id":4550083,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-11-17T16:53:57.000Z","date":"2016-11-15","kind":"exercise","acquired":true,"shares":2805,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":92128,"source":{"system":"sec-edgar","filing":"0001209191-16-150916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919116150916/doc4.xml","form_type":"4"}},{"id":4557409,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-11-14T16:45:26.000Z","date":"2016-11-11","kind":"sale","acquired":false,"shares":2500,"price":19.37,"value":48425.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $19.30 to $19.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":89323,"source":{"system":"sec-edgar","filing":"0001209191-16-149731","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919116149731/doc4.xml","form_type":"4"}},{"id":4557408,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-11-14T16:45:26.000Z","date":"2016-11-10","kind":"sale","acquired":false,"shares":2500,"price":20.3,"value":50750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $19.55 to $21.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":91823,"source":{"system":"sec-edgar","filing":"0001209191-16-149731","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919116149731/doc4.xml","form_type":"4"}},{"id":4580025,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-10-13T17:22:14.000Z","date":"2016-10-12","kind":"sale","acquired":false,"shares":2500,"price":16.41,"value":41025.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $16.35 to $16.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":94323,"source":{"system":"sec-edgar","filing":"0001209191-16-145821","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919116145821/doc4.xml","form_type":"4"}},{"id":4580024,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":168172,"kind":"person","name":"MCGRATH JOHN","position":1,"cik":"0001205442","reported_name":"MCGRATH JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-10-13T17:22:14.000Z","date":"2016-10-11","kind":"sale","acquired":false,"shares":2500,"price":18.52,"value":46300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $18.30 to $18.675. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":96823,"source":{"system":"sec-edgar","filing":"0001209191-16-145821","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205442/000120919116145821/doc4.xml","form_type":"4"}}]}